Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Matthew Baron's Application for Frederick Banting and Charles Best Canada Graduate Scholarships
FY 2013-14
Summary
The PBDs represent a significant health burden in Alberta, elsewhere in Canada, and internationally, with a conservative estimate of birth incidence of 1/50,000. In terms of genetic disease the PBDs may be medium-rare, yet they exact a very large toll on the health care system and on the families involved because of their severity. The PBDs include the Zellweger spectrum disorders (ZSDs), which range from severe, classical Zellweger syndrome to the milder infantile Refsum disease, and the Rhizomelic Chondrodysplasia Punctata spectrum (RCDP) All the PBDs are associated with compromised assembly of an organelle called the peroxisome, resulting in complex sequelae affecting the brain, eye, lung, liver and skeleton. The peroxisome is responsible for oxidation of very-long chain fatty acids (VLCFAs) and the synthesis of plasmalogens (PLs, a type of ether phospholipid), bile acids and docosahexaenoic acid, which are critical for pathways functioning during early child development. Mutations in 14 core peroxisome assembly (PEX) genes are currently known to cause the PBDs. Defects in any of 13 PEX genes result in the ZSDs, whereas RCDP is caused by defects in PEX7. There is a direct correlation between disease severity and the residual function of the proteins encoded by mutated PEX genes. Notably, since PBDs clearly represent an “inborn error of metabolism” type of defect, we anticipate that with increased knowledge of the genetic and physiological basis of tissue specific defects caused by PDBs we will be able to circumvent chemically, at least partially, the symptoms associated with these congenital diseases. Understanding the requirements for peroxisomes in tissue development and homoeostasis using simple animal models amenable to genetic and cell biological analyses will generate knowledge that can be translated to improved patient care and identification of novel targets for PBD therapy. We have established a fly model that recapitulates some of the phenotypes associated with the human PBDs and which provides the opportunity to 1) have a rapid and inexpensive way to investigate independently the requirements for peroxisomes in tissue development and homoeostasis and 2) develop unique ways to probe tissue-specific defects associated with the PBDs given the genetic techniques available in flies that we can use to inform further experimentation in mammalian models. The hypothesis that I will be testing is that PEX1 and PEX7 mutations often found in human PBD patients cause tissue-specific (e.g. neural) defects in developing embryos and that the effects of these mutations can be modified by targeting specific genetic pathways or introduction of small molecules. Validation of the Pex1 mutant homologues and Pex7 phenotypes as valid models of human peroxisome diseases will facilitate future high-throughput drug screening for small molecules that can improve the function of these mutations. Similarly, the screen for pathways that enhance or suppress the Pex1 mutant and Pex7 effects in S2 cells will identify further pathways that can be targeted in future drug screens.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311924
Name
Baron Matthew N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Matthew Baron's Application for Frederick Banting and Charles Best Canada Graduate Scholarships
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Developmental Defects; Drosophila Melanogaster; Fatty-Acid Metabolism; Genetic Disorders; Metabolic Disorders; Neuronal Defects; Peroxisomal Biogenesis Disorders; Peroxisomes; Tissue Development; Zellweger Spectrum Disorders
Abstract
The PBDs represent a significant health burden in Alberta, elsewhere in Canada, and internationally, with a conservative estimate of birth incidence of 1/50,000. In terms of genetic disease the PBDs may be medium-rare, yet they exact a very large toll on the health care system and on the families involved because of their severity. The PBDs include the Zellweger spectrum disorders (ZSDs), which range from severe, classical Zellweger syndrome to the milder infantile Refsum disease, and the Rhizomelic Chondrodysplasia Punctata spectrum (RCDP) All the PBDs are associated with compromised assembly of an organelle called the peroxisome, resulting in complex sequelae affecting the brain, eye, lung, liver and skeleton. The peroxisome is responsible for oxidation of very-long chain fatty acids (VLCFAs) and the synthesis of plasmalogens (PLs, a type of ether phospholipid), bile acids and docosahexaenoic acid, which are critical for pathways functioning during early child development. Mutations in 14 core peroxisome assembly (PEX) genes are currently known to cause the PBDs. Defects in any of 13 PEX genes result in the ZSDs, whereas RCDP is caused by defects in PEX7. There is a direct correlation between disease severity and the residual function of the proteins encoded by mutated PEX genes. Notably, since PBDs clearly represent an “inborn error of metabolism” type of defect, we anticipate that with increased knowledge of the genetic and physiological basis of tissue specific defects caused by PDBs we will be able to circumvent chemically, at least partially, the symptoms associated with these congenital diseases. Understanding the requirements for peroxisomes in tissue development and homoeostasis using simple animal models amenable to genetic and cell biological analyses will generate knowledge that can be translated to improved patient care and identification of novel targets for PBD therapy. We have established a fly model that recapitulates some of the phenotypes associated with the human PBDs and which provides the opportunity to 1) have a rapid and inexpensive way to investigate independently the requirements for peroxisomes in tissue development and homoeostasis and 2) develop unique ways to probe tissue-specific defects associated with the PBDs given the genetic techniques available in flies that we can use to inform further experimentation in mammalian models. The hypothesis that I will be testing is that PEX1 and PEX7 mutations often found in human PBD patients cause tissue-specific (e.g. neural) defects in developing embryos and that the effects of these mutations can be modified by targeting specific genetic pathways or introduction of small molecules. Validation of the Pex1 mutant homologues and Pex7 phenotypes as valid models of human peroxisome diseases will facilitate future high-throughput drug screening for small molecules that can improve the function of these mutations. Similarly, the screen for pathways that enhance or suppress the Pex1 mutant and Pex7 effects in S2 cells will identify further pathways that can be targeted in future drug screens.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Baron, Matthew N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~